<<Disclaimer: Verify this information before applying it to your situation.>> Dr. Robert Anderson continues to promote a celiac disease vaccine currently in development by his Victoria, Australia company, Nexpep. Little information is being made available about this gluten peptide- based vaccine, but phase I trials are supposed to begin in 2008 limited to HLA-DQ2 celiac disease patients. The Nexpep website states: "The vaccine will include the gluten peptides most commonly recognised by T cells in people with celiac disease. This general approach has been highly successful in non-human models of immune diseases and in people with cat-sensitive asthma. It is also under active investigation in Type 1 diabetes, multiple sclerosis and rheumatoid arthritis." From this statement I have pulled together some related abstracts and articles which discuss T-cell reactive peptide vaccines (see below). These vaccines appear to have shown only limited success in the past. They may only lessen symptoms and require repeated injections if they work at all. This approach does not look as promising as the Recombinant T-cell Receptor Ligand (RTL) drug immunotherapy being developed in Oregon which I previously discussed in my last post. ---------- Nexpep < http://www.nexpep.com.au/nex/ > (See the Science) ---------- Vaccine hope for food disease sufferers By KAMALA HAYMAN - The Press | Monday, 28 May 2007 < http://www.stuff.co.nz/stuff/4075010a11.html > ---------- Am. J. Respir. Crit. Care Med., Vol 154, No. 6, 12 1996, 1623-1628. Treatment of cat allergy with T-cell reactive peptides PS Norman, JL Ohman Jr, AA Long, PS Creticos, MA Gefter, Z Shaked, RA Wood, PA Eggleston, KB Hafner, P Rao, LM Lichtenstein, NH Jones and CF Nicodemus < http://ajrccm.atsjournals.org/cgi/content/abstract/154/6/1623 > ---------- Allergen immunotherapy: therapeutic vaccines for allergic diseases Geneva: January 2 7—29 1997 < http://www.eaaci.net/media/PDF/W/275.pdf > ---------- Special Feature: Therapeutic intervention in multiple sclerosis: Present practice and emerging prospects Immunology and Cell Biology (1998) 76, 83–90; Effects of vaccination with T cell receptor peptides: Epitope switching to a possible disease-protective determinant of myelin basic protein that is cross-reactive with a TCR BV peptide Arthur A Vandenbark, Yuan K Chou, Ruth Whitham, Dennis N Bourdette, and Halina Offner < http://www.nature.com/icb/journal/v76/n1/full/icb199810a.html > ---------- Arthritis & Rheumatism Volume 41, Issue 11 , Pages 1919 - 1929 T cell receptor peptide vaccination in rheumatoid arthritis: A placebo- controlled trial using a combination of V3, V14, and V17 Peptides Larry W. Moreland, Elizabeth E. Morgan, Thomas C. Adamson III, Zdenka Fronek, Leonard H. Calabrese, Joseph M. Cash, Joseph A. Markenson, Alan K. Matsumoto, Joan Bathon, Eric L. Matteson, Kristine M. Uramoto, Cornelia M. Weyand, William J. Koopman, Louis W. Heck, Vibeke Strand, Jocelyn P. Diveley, Dennis J. Carlo, Christopher J. Nardo, Steven P. Richieri, Steven W. Brostoff (Paste link together on 1 line.) < http://www3.interscience.wiley.com/cgi- in/abstract/85008837/ABSTRACT > ---------- PNAS, Apr 15 1991; 88 (8), 3088-3091 Vaccination Against Autoimmune Mouse Diabetes with a T-Cell Epitope of the Human 65-kDa Heat Shock Protein D Elias, T Reshef, OS Birk, R van der Zee, MD Walker and IR Cohen < http://www.pnas.org/cgi/content/abstract/88/8/3088 > * * * Visit the Celiac Web Page at Http://www.enabling.org/ia/celiac/index.html Archives are at: Http://Listserv.icors.org/SCRIPTS/WA-ICORS.EXE?LIST=CELIAC